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The search for new organic and inor-
ganic compounds for treatment of differ-
ent types of diseases is the aim of intense
study. Over the past decades, many new
compounds have been synthesized and
isolated from numerous sources. However,
only a fraction of them have demonstrated
activity against human diseases. Despite
the progress in research, the morbidity
and mortality of several diseases including
cancer, cardiovascular diseases, and HIV
remains a major worldwide health prob-
lem. The effectiveness of currently avail-
able drugs is limited by high toxicities, low
permeability, low half-life, and intrinsic
or acquired drug resistance (Fesik, 2005;
Gonzalez-Angulo et al., 2007). On this
basis, it is crucial to search for novel
molecules with high potency, low toxic-
ity, and mutagenicity with selective activ-
ities that are able to overcome frequently
developed resistance to available drugs.
The challenging part in medicinal and
pharmaceutical research is to differenti-
ate between normal and affected cells
and targets. For example, specific acti-
vation of cell death only in cancer cells
without hampering normal healthy cells
is one of the most difficult and hardest
problems faced. However, this challenge
opens up possibilities for conducting new
medicinal and pharmaceutical research.
Significant successes have also been real-
ized in many research areas including:
central nervous system, pulmonary sys-
tem, oncology, infectious diseases, inflam-
mation, cardiovascular, metabolism, and
HIV. This has been possible because of
the discovery of a number of new cellular
targets including enzymes, synthetic path-
ways, novel reagents, development of new
and target validation methods. Although
inhibition of enzymes by small molecules
and the identification of some of their
targets have been confirmed, an improve-
ment of the efficacy by structure-activity
relationship studies using the computer-
assisted data has failed in some instances.
This is not surprising since many drugs
can attack the diseased and normal cells in
a variety of ways. For example, adriamycin
was shown to be a DNA binding agent for
many years. But, polymeric conjugates of
adriamycin exert anticancer activity with-
out entering into the cell nucleus (Tritton
and Yee, 1982; Tritton, 1991). It was found
that the drug-conjugate was located at the
cell membrane and adriamycin was still
bound to the polymer.
Our research group has been involved
in the development of new anticancer
agents which have not been explored
systematically1. Our endeavor in this area
has not been smooth and problem free
because we have used polyaromatic amine
derivatives as key components in our
molecules. The main criticisms were that
thesemolecules could generatemutagenic-
ity in the cell. Extensive research has con-
firmed that certain polycyclic aromatic
compounds are mutagenic and carcino-
genic. Does this mean that all polycyclic
aromatic compounds are mutagenic? The
obvious answer is “no.” The fundamen-
tal organic compound benzene is car-
cinogenic, but several hundred benzene
derived compounds are extremely useful
drugs. Numerous anthracyclines, metal-
containing molecules, and mustards are
presently in clinical use.
The chemistry, biology, pharmacol-
ogy, medicinal/pharmaceutical values of
β-lactams are investigated extensively.
1http://portal.utpa.edu/utpa_main/daa_home/cosm_
home/chem_home/chem_faculty/chemistry_banik
A number of β-lactams that have been
widely used in humans and animals
are very safe antibiotics. We hypothe-
sized that novel β-lactam drugs can be
designed and synthesized which will have
both an enhanced anticancer activity and
low toxicity to normal tissue. We have
designed, synthesized, and tested numer-
ous β-lactams in racemic and chiral forms
and have shown that many of them pos-
sess excellent antitumor activity in vitro
against human cancer cell lines such as
ovarian, skin, breast, colon, leukemia,
prostate, and pancreatic cancer cell lines
at low concentration in vitro and in vivo
(Banik et al., 2003, 2004, 2005, 2010a,b,c;
Bandyopadhyay et al., 2009, 2010, 2012;
Bandyopadhyay and Banik, 2010; Banik
and Becker, 2010a; Banik, 2011, 2012;
Shaikh et al., 2011; Banik and Manhas,
2012; Shaikh and Banik, 2012). In some
examples, the activity has exceeded that of
cisplatin, a well-known anticancer drug.
The active β-lactams block G2/M and
G0/M checkpoints in cancer cell lines.
Importantly, it has been observed that
these β-lactams are less toxic to mice than
some known clinically active drugs and
were non-mutagenic when tested in bacte-
rial and animal systems.This study may be
used to develop translational science using
β-lactam anticancer agents following cell-,
animal- and gene-based approaches.
Despite an enormous body of work that
describes the cellular reaction of polycyclic
aromatic hydrocarbon (PAH), the appli-
cation of these derivatives as anticancer
agents has not been explored systemati-
cally. Our work in this area has culminated
in the synthesis of a large number of pla-
nar molecules using highly lipophilic poly-
cyclic aromatic amines as the nucleus for
a systematic examination of modifications
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of structures that might result in selec-
tive interactions with cancer cells. This
study has established lead compounds that
are very effective against a variety of can-
cer cell lines. From structure-activity and
in vitro and in vivo studies, lead com-
pounds that are highly potent in HT-29
(human colon) and SKOV-3 (human ovar-
ian) cell lines have been developed. They
were shown to produce selective apop-
tosis in HL-60 cell lines. Although the
major focus of therapeutic studies in can-
cer chemotherapy has been alterations of
DNA replicative and repair functions, our
studies have suggested that interactions
with cell membranes may also play an
important role in anticancer effectiveness1
(Becker and Banik, 1998; Becker et al.,
2000; Banik and Becker, 2001a,b, 2010b;
Banik et al., 2010d).
These explorations have taught me
numerous lessons which I would like to
share with. Unless we recruit dedicated
and creative students, postdoctoral fel-
lows and scientists in tackling some of
the most challenging problems, there will
be no progress made. Creativity does
not really depend on the age although
it has some influence on experience.
In science classes the understanding of
concepts and the ability to solve prob-
lems should be emphasized over memo-
rization. Students should be encouraged
to develop their own problem-solving
strategies. In particular, organic, medici-
nal/biochemists/pharmacists have to know
how to design a molecule, what reaction
to perform, which reagents and experi-
mental conditions to use during the devel-
opment of medicinal drugs and pathways
(how these drugs interact with the cell and
cure medical disorders). Thus, problem
solving is crucial in learning and practic-
ing science. A researcher has to emphasize
that research does not always proceed the
way it is planned and that it is crucial to
identify all the possibilities. This may turn
out that the undesired products are more
crucial than what we wanted to prepare.
During the course of our investigation,
we have not obtained results predicted by
many significant researchers. It was dif-
ficult to convince the scientific commu-
nity some of the unprecedented science.
However, appropriate support from exper-
iments, instrumental work, and evidences
have greatly facilitate our research. We see
lots of changes are going in the academic,
industry and business areas. These changes
may be necessary for the future prospect of
our generations. One should keep in mind
that this process should not dishearten
bright scientists. No strong research pro-
gram in chemistry and pharmacy can be
built without the assistance and direct par-
ticipation of creative scientists.
Out of 10,000 molecules synthesized or
isolated for medicinal and pharmaceuti-
cal research, only one becomes clinically
active per year. The entire process required
10–18 years. Why do we make such low
progression despite our combined efforts
with numerous sophisticated methods and
tools? As scientists in medicinal and phar-
maceutical research, it is our duty to
explore our field with no set boundaries.
Perhaps we are overlooking or overthink-
ing crucial steps that are of importance and
have medicinal value. Not all molecules
that are designed or isolate have a planned
biological activity. In many cases deter-
mining whether or not a molecule will
exhibit any activity is a difficult process.
We have little control over the activities
of most of the molecules that are syn-
thesized or isolated, but we do have con-
trol over the approach as to the discovery
success. Every step is crucial for success,
starting from the basics of drug design,
synthesis, alteration of structure, and test-
ing of molecules. It has been established
by many groups that the most obvious
route to discovery is often not the best. A
compound designed for a particular dis-
ease may have other significant therapeutic
applications. An identification of syner-
gistic effects of two drugs and drug-drug
interactions in living cells are very com-
plex process. Although many patients take
multiple drugs every day to remain healthy
and this may prevent one-form of disease.
How can we be certain that these multiple
drugs would not demonstrate serious side
effects whichmay be life threatening? Since
manymedicinal and pharmaceutical prod-
ucts have become our friends in the fight
against diseases through non-traditional
methods due to serendipity, we should
follow the experiments carefully with
dedication. Each step requires the best
efforts capable of each scientist. Only as a
whole are we capable of brightening our
future in medicinal and pharmaceutical
research.
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